Journal
MALARIA JOURNAL
Volume 12, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1475-2875-12-177
Keywords
-
Categories
Funding
- Institut Pasteur de Madagascar [MDG-910-G19-M]
- University of North Carolina, USA from the National Institutes of Health [AI089819]
- National Institutes of Health [5T32AI0715132]
- North Carolina Clinical and Translational Science Award [UL1RR025747]
- Directorate For Geosciences [1115057] Funding Source: National Science Foundation
Ask authors/readers for more resources
In endemic areas, Plasmodium vivax relapses are difficult to distinguish from new infections. Genotyping of patients who experience relapse after returning to a malaria-free area can be used to explore the nature of hypnozoite activation and relapse. This paper describes a person who developed P. vivax malaria for the first time after travelling to Boriziny in the malaria endemic coastal area of Madagascar, then suffered two P. vivax relapses 11 weeks and 21 weeks later despite remaining in Antananarivo in the malaria-free central highlands area. He was treated with the combination artesunate + amodiaquine according to the national malaria policy in Madagascar. Genotyping by PCR-RFLP at pvmsp-3 alpha as well as pvmsp1 heteroduplex tracking assay (HTA) showed the same dominant genotype at each relapse. Multiple recurring minority variants were also detected at each relapse, highlighting the propensity for multiple hypnozoite clones to activate simultaneously to cause relapse.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available